Spectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepView® System
Spectral AI, Inc. (Nasdaq: MDAI) ('Spectral AI” or the 'Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care ...
3d
Why did my GP just use Google? What I’ve learned about the health system, as a doctor and a patient
From the importance of looking up ailments to the comfort and cleanliness of hospitals, Roland Bull has experienced both sides of the bed as a patient-turned-doctor ...
Ibex Medical Analytics (Ibex), a leader in clinical-grade AI-powered pathology, today announced a strategic collaboration with HNL Lab Medicine, a leading multi-regional medical laboratory in the ...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging ...
BEIJING, CHINA - Media OutReach Newswire - 20 March 2026 - China's multifaceted strategy to end the tuberculosis ...
Milestone marks the half-way point of enrollment in pivotal U.S. study designed to support 510(k) submission for the first culture-free, rapid phenotypic ID/AST panel for critically ill pneumonia ...
Hyperfine, Inc. (NASDAQ:HYPR) Q4 2025 Earnings Call Transcript March 18, 2026 Hyperfine, Inc. beats earnings expectations. Reported EPS is $-0.06276, expectations were $-0.08. Operator: Hello, and ...
Duc Giang, Saint Paul, and Hanoi Oncology Hospital. The technology is expected to assist doctors in reading film results and ...
Calculator could streamline assessment and standardize urine testing in febrile preverbal children in emergency departments.
Is DHR a good stock to buy? We came across a bullish thesis on Danaher Corporation on Buffett_N_Me’s Substack. In this article, we will summarize the bulls’ thesis on DHR. Danaher Corporation’s share ...
ASX-listed healthcare companies are increasingly teaming up with universities to fast-track new therapies, combining academic research with clinical and commercial ... Read More The post ASX ...
The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results